Johnson & Johnson (JNJ) Shares Bought by Raymond James Trust N.A.

Raymond James Trust N.A. lifted its stake in Johnson & Johnson (NYSE:JNJ) by 2.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 158,114 shares of the company’s stock after acquiring an additional 4,506 shares during the period. Johnson & Johnson accounts for about 1.3% of Raymond James Trust N.A.’s investment portfolio, making the stock its 9th largest position. Raymond James Trust N.A.’s holdings in Johnson & Johnson were worth $20,404,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of JNJ. Horan Securities Inc. boosted its stake in Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after buying an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 80 shares in the last quarter. FNY Investment Advisers LLC boosted its stake in Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after buying an additional 428 shares in the last quarter. CKW Financial Group boosted its stake in Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after buying an additional 128 shares in the last quarter. Finally, Mackey Komara & Dankovich LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $148,000. 66.91% of the stock is currently owned by institutional investors and hedge funds.

JNJ stock opened at $138.61 on Monday. The firm has a market cap of $371.88 billion, a PE ratio of 16.94, a PEG ratio of 2.40 and a beta of 0.67. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The company had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the previous year, the company posted $2.06 earnings per share. The firm’s quarterly revenue was up .1% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be paid a dividend of $0.95 per share. The ex-dividend date is Friday, May 24th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.74%. Johnson & Johnson’s payout ratio is 44.01%.

Several analysts recently commented on JNJ shares. Barclays reaffirmed an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Credit Suisse Group boosted their price target on Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Citigroup boosted their price target on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Finally, Raymond James boosted their price target on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $147.30.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Bought by Raymond James Trust N.A.” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/20/johnson-johnson-jnj-shares-bought-by-raymond-james-trust-n-a.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Cost of Equity For A Business, Investors

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.